The Role of Acute Combined PPAR Alpha and Gamma Stimulation on Insulin Action in Humans

Plain-language summary

This study examines the effect of the drug pioglitazone and PPAR alpha-gamma stimulation on how insulin works in the body, compared with placebo, in patients with type 2 diabetes. It enrolled individuals with type 2 diabetes. The research was conducted in Phase 4 and has been completed.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

Phase 4

Status

Completed

Sponsor

Albert Einstein College of Medicine

Intervention

Pioglitazone, Placebo, Pancreatic Clamp Study

Start date

12/1/2000

Estimated completion

7/1/2011

Countries

United States

Related genes

Locations

• The Bronx, United States

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

• Individuals with Type 2 Diabetes

Exclusion Criteria:

* Individuals with bleeding disorders including gastrointestinal reflux disease (GERD), peptic ulcer disease (PUD), any gastrointestinal (GI) bleeding
* High blood pressure
* History of Coronary Artery Disease or chest pain on exertion